<DOC>
	<DOC>NCT02865928</DOC>
	<brief_summary>This is a randomized, double-blinded, placebo-controlled trial of serratus plane blocks in subjects undergoing outpatient unilateral or bilateral breast surgery. Ninety subjects will be enrolled into the study at presurgical testing. Subjects will be stratified based on surgery type and randomized to receive a serratus plane block with either bupivicaine HCL or placebo. All patients will receive standard intraoperative anesthesia and standard postoperative pain control. The primary endpoint is the amount of opioid administered postoperatively. Secondary endpoints include postoperative pain intensity at timed intervals, amount of opioid administered intraoperatively and postoperatively, incidence of nausea and vomiting, time to discharge and patient satisfaction</brief_summary>
	<brief_title>Serratus Plane Block for Postoperative Pain Control</brief_title>
	<detailed_description />
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>ASA IIII. Undergoing outpatient breast surgery requiring general anesthesia, including but not limited to mastectomy, lumpectomy, reconstruction with tissue expanders or implants and reconstruction revision. Unable to provide informed consent. Patients who are pregnant or nursing. ASA IVV. Alcohol or narcotic dependence in the last 2 years. Concurrent condition requiring regular use of analgesia that may confound postsurgical assessments as determined by principle investigator. Hepatic disease. Allergies to amide anesthetics as determined from medical history or patient selfreport. Evidence of infection at injection site. Contraindication to pain medications such as acetominophen, morphine, oxycodone, keterolac, dilaudid, Toradol. Body weight &lt;50kg. BMI&gt;40kg/m2. History of hypotension. Abnormal renal (creatinine &gt; 1.5 mg/dL) function. Heart block. Any physical, mental or medical condition, that in the opinion of the investigator, makes study participation inadvisable.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>